Alchemy High Growth

Scheme Rating

IME Scheme Rating

3 of 5 stars

Wait for performance to improve: Alchemy has all the ingredients of a quality PMS provider. However, the performance of Alchemy High Growth has been particularly weak (relative to peers, benchmarks, and even other Alchemy schemes). We would wait for the performance to improve before recommending investments in this scheme. Initial signs of this recovery are evident since CY23.

IME Strategy Rating

4 of 5 stars

GARP Approach: The Strategy follows a GARP (Growth at a Reasonable Price) approach, leveraging the belief in India’s high-growth economy and robust entrepreneurial culture. With a focused portfolio of up to 25 stocks selected from the top 500 companies, it maintains a 3-5 years investment horizon. It aims at a Multi-cap strategy that follows a ‘top-down’ and ‘bottom-up’ stock-picking approach. The strategy is relatively flexible in terms of definition, allowing the fund manager to shift between investment styles & market capitalizations based on the best opportunities in the market at a specific point in time.

PMS Scheme Ratings are driven by IME’s Proprietary Scheme Rating Methodology, which takes into account our ratings of the Scheme’s investment strategy, its maturity, the investment team, and our separate rating on the AMC that runs this particular scheme. Our views on each of these individual criteria are available via the IME RMS – which you can view by reaching out to one of our relationship managers (using either the live chat or book appointment feature on this site).

IME View on Alchemy High Growth

Type: Large & Midcap | GARP | AUM (973.7 cr) | Inc Date (08 May 2002)

Alchemy High Growth- Investment Strategy

Following concentrated exposure to generate long term returns by investing in all market caps

Alchemy High Growth is a multi-cap strategy that follows a ‘top-down’ and ‘bottom-up’ stock-picking approach. The portfolio will be managed under the following investment criteria – 20 to 25 stocks – Min of 25% in large-caps, Max of 20% in small-caps, balance in Mid-caps – While there is a bias towards mid-caps, the portfolio has the flexibility to position the portfolio based on external opportunities.

Investment Process 

The investment process is driven by a 3 I matrix:

  •  Idea Generation: Track a larger investment universe. With actively tracking the larger universe, idea generation happens through network inputs (independent company/sector feedback, interacting with peer group, and from sector conference). 
  • Investment Process: Investment process managed by the CIO with veto power at various stages of the research process. Continuous monitoring and periodic reviews of the position on a quarterly basis.
  • Intervention: Intervention based on CIO’s veto power in portfolio construction, and exit strategy.


Trailing Performance

1yr 3yr 5yr Since Inception
Alchemy High Growth 51.1 19.8 12.6 20.7
S&P BSE 500 TRI 39.5 19.5 19 17.4
Alpha over Broad Mkt BM 11.6 0.3 -6.4 3.3
Nifty 500 38.4 18.1 17.5
Alpha over Category BM 12.7 1.7 -4.9

Performance as of: 28-Feb-23 | Inception Date: 08-May-02

Fund Managers

Alok Agarwal | 4-star rated FM

FM | 16 yrs Experience | 2 yrs at current firm

Past Experience: PGIM, Deutsche AMC and K.R Choksey

Alok Agarwal brings more than 16 years of FM experience. Prior to this, He was associated as a FM with PGIM, Deutsche AMC and K.R Choksey. He is a CFA and CMT.

Fee Structure

Fee StructureFee
Fixed Fee Structure2.5
Variable Fee Structures1.5% fixed + 15% above 10% hurdle
Exit Fees1yr(1%)


AMC: Alchemy PMS (click link for detailed AMC review)

Not a top recommendation (at this time) due to weak recent performance: Backed by solid founders, a CIO that is a co-founder and well-respected investor and a long track record of identifying interesting bottom-up investment opportunities, Alchemy has all the ingredients for a successful PMS business. However, their performance has been very sub-par in recent years, and it is this underperformance that is the primary reason behind Alchemy not being a 5 or 4-star rated PMS.

AMC Rating

3 of 5 stars

AMC Pedigree

4 of 5 stars

AMC Size

4 of 5 stars

Team Pedigree

5 of 5 stars

Inv Philosophy

3 of 5 stars


3 of 5 stars

Get substantially greater insights by connecting with us!

Details shared on the public website, are only a short snapshot of the more detailed analysis that resides in our Proprietary Research Management Solution (RMS) – A proprietary cloud-based tool, that ensures that the unbiased research insights of our central research team are shared directly with investors.

Our RMS allows us to operate with a level of transparency, ethics & consistency of insights, that is unparrarelled in the industry. Our RM’s will help showcase the PMS/AIF options that are the most suited for your unique requirements.

Download Sample RMS Reports: AMC View | Scheme Comparison

Note: PMS AMC & Scheme Reviews and Ratings are based on IME Capital’s Proprietary Review and Rating Methodology (read more here: AMC Rating & Scheme Ratings). These reflect the unbiased views of our central research team, based on our assessment of the investment value of these PMS/AIF strategies for our investors. We follow a highly stringent rating-criteria, where approximately 50% of PMS AMC’s & strategies would be rated 2-star or below (this is not meant to indicate that these funds are not investment-worthy, but that they do not currently fulfill the requirements we focus on for recommending funds to our investors — based on our internal views on the merit of the AMC/strategy relative to peers). Reviews & Ratings are primarily based on research of publicly available information (SEBI disclosures, PMS websites, PMS-aggregation platforms, webinar recording, media interviews etc.) and no explicit consent is required from AMCs for the same. While we endeavour to do further due-diligence via direct interactions with the investment teams of AMCs, this is typically restricted to AMC’s that meet our foundational fund selection criteria (reviews on lower-rated AMCs are often based solely on publicly available information). The views reflected in our Reviews & Ratings, are our independent views and may not be shared by the AMC’s and the investment teams. Please read detailed disclaimer for more.